STOCK TITAN

Oncternal Therapeutics Inc - ONCT STOCK NEWS

Welcome to our dedicated news page for Oncternal Therapeutics (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncternal Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncternal Therapeutics's position in the market.

Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) to participate in a virtual fireside chat on new treatment options for prostate cancer. President and CEO to discuss the development of ONCT-534, a dual-acting androgen receptor inhibitor, and its potential in advanced prostate cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) provides a business update and financial results for the fourth quarter of 2023. The company's Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor for advanced prostate cancer, is progressing well with encouraging initial response signals. ONCT-808, an autologous CAR T cell therapy for aggressive B-cell lymphoma, also shows promising results. The company has a cash runway projected into 2025, with $34.3 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
earnings
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) will report Q4 and full year 2023 financial results on March 7, 2024. A webcast will follow to discuss business updates and financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.85%
Tags
earnings
Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced that its President and CEO, James Breitmeyer, M.D, Ph.D., will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be held virtually, and the webcast link will be available on the company's website for at least 30 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. announced the approval of an inducement award for a new employee, Damien Bresson, who will be joining as Senior Director, Preclinical and Translation Science. The award consists of an option to purchase 4,500 shares of Oncternal common stock, with a 10-year term and vesting over a four-year period. The award was approved by Oncternal’s compensation committee and will be granted as an inducement material to the employee entering into employment with Oncternal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
-
Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ONCT), announced the enrollment of the fourth patient in its Phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor, for advanced prostate cancer. The study utilizes an adaptive Bayesian Optimal Interval (BOIN) design, with the last two patients enrolled in the third dosing cohort at 160 mg/day. The decision to proceed to dose level 3 was confirmed by the study’s Safety Review Committee (SRC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
clinical trial
Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ONCT), has announced a 1-for-20 reverse stock split of its common stock effective January 8, 2024. The split aims to bring the company into compliance with Nasdaq's minimum bid price requirement, with no change in par value or authorized shares. All outstanding stock options, warrants, and equity incentive plans will be proportionately affected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1398.4%
Tags
none
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announces approval of an inducement award for new employee Rebecca Nolan-Olson, consisting of an option to purchase 19,500 shares of Oncternal common stock under the 2021 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
-
Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provides an update on its Phase 1/2 Study ONCT-808-101 for the ROR1-targeting autologous CAR T cell therapy ONCT-808 in patients with relapsed or refractory aggressive B-cell lymphoma. Initial results show promising complete and partial responses, with some adverse events. However, a fatal serious adverse event was reported in a patient at a higher dose level, prompting protocol changes and communication with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
clinical trial
Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provided a business update and reported third quarter 2023 financial results. They announced the dosing of the first patient in the Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor, for advanced prostate cancer treatment. They also treated additional patients in the ongoing Phase 1/2 study for ONCT-808, an autologous CAR T cell therapy, for aggressive B-cell lymphoma. The company has $40.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023, with a cash runway projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
earnings
Oncternal Therapeutics Inc

Nasdaq:ONCT

ONCT Rankings

ONCT Stock Data

26.64M
2.66M
8.41%
16.14%
0.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ONCT

oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic